These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 37762203)

  • 1. Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies.
    Buccellato FR; D'Anca M; Tartaglia GM; Del Fabbro M; Scarpini E; Galimberti D
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach.
    Morató X; Pytel V; Jofresa S; Ruiz A; Boada M
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
    Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
    Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conventional Versus New Treatment: Comparing the Effects of Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Receptor Antagonist With Aducanumab.
    Chin E; Jaqua E; Safaeipour M; Ladue T
    Cureus; 2022 Nov; 14(11):e31065. PubMed ID: 36475205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapeutic combinations for the treatment of Alzheimer's disease.
    Nagata T; Shinagawa S; Nakajima S; Noda Y; Mimura M
    Expert Opin Pharmacother; 2022 Apr; 23(6):727-737. PubMed ID: 35230200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Causal treatment of Alzheimer's disease: amyloid antibodies].
    Pawlowski M; Warnecke T
    Inn Med (Heidelb); 2022 Sep; 63(9):1000-1008. PubMed ID: 35290498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical Appraisal of Amyloid Lowering Agents in AD.
    Decourt B; Boumelhem F; Pope ED; Shi J; Mari Z; Sabbagh MN
    Curr Neurol Neurosci Rep; 2021 Jun; 21(8):39. PubMed ID: 34110536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer's Disease.
    Saeedi M; Mehranfar F
    Recent Pat Biotechnol; 2022; 16(2):102-121. PubMed ID: 35236274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs.
    Varadharajan A; Davis AD; Ghosh A; Jagtap T; Xavier A; Menon AJ; Roy D; Gandhi S; Gregor T
    J Neurosci Rural Pract; 2023; 14(4):566-573. PubMed ID: 38059250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aducanumab for Alzheimer's disease: A regulatory perspective.
    Nisticò R; Borg JJ
    Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease: Recent treatment strategies.
    Vaz M; Silvestre S
    Eur J Pharmacol; 2020 Nov; 887():173554. PubMed ID: 32941929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets.
    Gu X; Qi L; Qi Q; Zhou J; Chen S; Wang L
    Biosci Trends; 2024 Mar; 18(1):49-65. PubMed ID: 38382942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies.
    Imbimbo BP; Ippati S; Watling M; Imbimbo C
    Pharmacol Res; 2023 Jan; 187():106631. PubMed ID: 36586644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease: Molecular aspects and treatment opportunities using herbal drugs.
    Thakral S; Yadav A; Singh V; Kumar M; Kumar P; Narang R; Sudhakar K; Verma A; Khalilullah H; Jaremko M; Emwas AH
    Ageing Res Rev; 2023 Jul; 88():101960. PubMed ID: 37224884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab.
    Shi M; Chu F; Zhu F; Zhu J
    Front Aging Neurosci; 2022; 14():870517. PubMed ID: 35493943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs)].
    Yamada M
    Brain Nerve; 2023 May; 75(5):464-469. PubMed ID: 37194514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling lecanemab as a treatment option for Alzheimer's disease.
    Schiller ER; Silverglate BD; Grossberg GT
    Expert Rev Neurother; 2024 May; 24(5):433-441. PubMed ID: 38566584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.